Keyphrases
Spain
100%
COVID-19
85%
Barcelona
53%
Tertiary Hospital
49%
Reinfection
44%
Whole Genome Sequencing
31%
Catalonia
29%
Vaccine Immunogenicity
22%
Socioeconomic Status
22%
Mortality Inequality
22%
Epidemiological Characteristics
22%
COVID-19 Cases
22%
Multiple Sclerosis
22%
Natalizumab
22%
Reactogenicity
22%
Vaccine Safety
22%
MRNA-1273
22%
Viral Lineage
22%
Living with
22%
COVID-19 Vaccination
22%
Natalizumab Treatment
22%
Effective Immunization
22%
Healthcare Workers
17%
Confidence Interval
16%
Revaccination
16%
Hepatitis A Virus
16%
Immunization
16%
Vaccination
16%
Hepatitis B Virus
16%
Pandemic Waves
14%
Primary Care
14%
Heterologous Booster
13%
Consensus Sequence
11%
Hospitalization
11%
Inactivated Vaccine
11%
Treatment Delay
11%
Virus Hepatitis
11%
Immunogenicity
11%
Annualized Relapse Rate
11%
Pre-vaccination
11%
T2 Lesions
11%
Seroprotection
11%
Expanded Disability Status Scale
11%
Tumefactive multiple Sclerosis
11%
Clinical Characteristics
10%
BNT162b2
8%
Homologous Booster
8%
Booster Dose
8%
T478K
7%
GISAID
7%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
61%
Reinfection
44%
SARS Coronavirus
44%
Hepatitis B Virus
30%
Messenger RNA
28%
Immunogenicity
28%
Diseases
28%
Vaccine
22%
Adverse Event
22%
Natalizumab
22%
Vaccine
22%
Messenger RNA
22%
COVID-19 Vaccine
22%
Infection
22%
Hepatitis B
22%
Prevalence
8%
Hepatitis A Virus
8%
Vaccine Efficacy
7%
Recurrence Risk
5%
Expanded Disability Status Scale
5%
Virus Hepatitis
5%
Inactivated Vaccine
5%
Sphingosine 1 Phosphate
5%
Disease Duration
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
44%
Reinfection
44%
COVID-19
26%
Socioeconomic Status
22%
COVID-19 Vaccination
22%
Reactogenicity
22%
Messenger RNA
22%
CD20
22%
Hepatitis B Virus
22%
Hepatitis B Vaccination
12%
Health Care
11%
Multiple Sclerosis
10%
Whole Genome Sequencing
8%
Booster Dose
7%
Vaccine Efficacy
7%
Seroconversion
6%
Mortality Rate
5%
